Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostaglandin I3 (PGI₃) is an eicosanoid derived from eicosapentaenoic acid (EPA). It acts as an anti-aggregatory agent by inhibiting platelet aggregation and promoting vasodilation, thereby playing a protective role against thrombosis. Its synthesis is mediated by cyclooxygenase (COX) and prostacyclin synthase enzymes. PGI₃, similar to its analog PGI₂, counteracts the pro-aggregatory effects of thromboxane A₂ (TXA₂), contributing to cardiovascular protection.
Inhibits platelet aggregation by increasing intracellular cAMP levels, leading to reduced thrombus formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostaglandin I3 (PGI₃).